In this article, we will take a look at the 10 Fast-Growing AI Healthcare Companies to Watch Right Now. In this piece, we take a closer look at Butterfly Network Inc. (NYSE:BFLY) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.
Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.
Why Medicine Could Be AI’s Next Major Market
Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.
Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.
These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.
A Low Share Price Does Not Always Mean Cheap
A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.
The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.
Finding the Best AI Medicine Stocks
This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.
The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.
CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.
Our Methodology
For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.
10 Best Cheap AI Medicine Stocks to Buy Now
8. Butterfly Network Inc. (NYSE:BFLY)
Butterfly Network, Inc. (NYSE: BFLY) reaches eighth place by attempting to change where and how medical imaging can be performed.
Traditional ultrasound equipment can be expensive, bulky and dependent on specialized operators. The company has developed portable ultrasound devices built around its proprietary Ultrasound-on-Chip technology, cloud software and artificial intelligence.
The long-term goal is to extend diagnostic imaging beyond conventional hospital imaging departments. Handheld ultrasound devices could be used in emergency rooms, ambulances, rural clinics, community-care facilities and medical schools.
Second-quarter 2026 revenue increased 39% to a record $32.6 million. U.S. revenue surged 57%, supported by higher probe sales and contributions from the company’s licensing and development partnerships.
The quarter also showed meaningful progress toward a more sustainable financial model. Gross margin expanded to 71.4%, compared with 63.7% one year earlier. Its adjusted EBITDA loss improved by 78% to approximately $1.4 million.
The company’s Compass AI platform is designed to help healthcare institutions manage ultrasound programs, workflows, documentation and device utilization. It signed six new enterprise software agreements during the quarter and continued expanding its pipeline.
The Butterfly Garden platform adds another potential source of growth by allowing third-party developers to create medical-imaging AI applications. Its embedded technology business could also generate licensing revenue from companies building new products around the ultrasound semiconductor platform.
Butterfly Network, Inc. (NYSE: BFLY) remains unprofitable and considerably smaller than the leading medical-technology companies. International revenue also declined during the second quarter, showing that its growth is not yet evenly distributed.
Still, the combination of affordable imaging hardware, enterprise software and artificial intelligence gives it a distinctive position among fast-growing healthcare AI companies. If management can turn growing enterprise interest into recurring software and licensing revenue, the business could become much more valuable than a simple handheld-device manufacturer.
YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
